Bexagliflozin Patent Expiration

1. Brenzavvy patent expiration

Drug Patent Number Company Drug Patent Title Drug Patent Expiry Activity Alert
These drug patents protects the active chemical substance. Only drug patent owner can launch products that use this active substance.
US8802637 THERACOSBIO Benzylbenzene derivatives and methods of use
Aug, 2028

(4 years from now)

US7838499 THERACOSBIO Benzylbenzene derivatives and methods of use
Jan, 2029

(4 years from now)

US10981942 THERACOSBIO Crystalline form of benzylbenzene SGLT2 inhibitor
Jun, 2031

(6 years from now)

US8987323 THERACOSBIO Crystalline form of benzylbenzene SGLT2 inhibitor
May, 2032

(7 years from now)

These drug patents focus on the other aspects of the active substance like dosage, mode of administration (oral, tablet, capsules, liquids etc).
US8106021 THERACOSBIO Benzylbenzene derivatives and methods of use
Aug, 2028

(4 years from now)

US10533032 THERACOSBIO Crystalline form of benzylbenzene SGLT2 inhibitor
Jul, 2031

(6 years from now)




Drug Exclusivity Drug Exclusivity Expiration
New Chemical Entity Exclusivity(NCE) Jan 20, 2028

NCE-1 date: 20 January, 2027

Market Authorisation Date: 20 January, 2023

Treatment: An adjunct to diet and exercise to improve glycemic control in adults with type 2 diabetes

Dosage: TABLET

More Information on Dosage

BRENZAVVY family patents

Family Patents